Newsroom

News

The Alliance of German Science Organisations strongly supports the Federal Government’s consistent action against Russia's belligerent attack on Ukraine, which is in violation of international law.

28.02.2022

News

For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a joint venture of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University (JMU) Würzburg, now demonstrate a new way to study CRISPR systems that can accelerate their conversion into tools. Their approach was published today in the journal Molecular Cell.

24.02.2022

HIRI

News

Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models.

18.02.2022

HZI Campus

News

An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School, describes the dual effect of the endogenous substance itaconic acid, which is both antiviral and anti-inflammatory. Their study, which has now appeared in the journal PLoS Pathogens, opens up perspectives for possible therapeutic applications of itaconic acid against severe courses of disease in viral infections.

17.02.2022

HZI Campus

TWINCORE

Fruchtkörper von Myxobakterien unter dem Lichtmikroskop

News

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections. Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof Rolf Müller and Prof Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr Thomas Hesterkamp and Evotec. The HIPS is a site of the HZI in collaboration with Saarland University.

04.02.2022

HZI Campus

HIPS

News

The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially in combating the SARS-CoV-2 pandemic, and the future development of infection research in Lower Saxony. He also delivered a message of thanks to the scientists at the research centre in Braunschweig.

04.02.2022

HZI Campus

Back to the first page
...
44
45
46
47
...
148

HZI in the media

Quelle: Pressemitteilung

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025

LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025

Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025

Augsburger Allgemeine

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025

bild der wissenschaft

could be reintroduced at any time. Epidemiologists at the Helmholtz Center for Infection Research (HZI) have now shown that many people do

23.10.2025

MSN.com

... eingeschleppt werden könnte. Epidemiolog:innen des Helmholtz-Zentrums für Infektionsforschung (HZI) haben nun gezeigt, dass ...

23.10.2025

innovations report

this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss

22.10.2025

Phys.org

Malaria-Medikamentes ermöglichen könnte. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

22.10.2025

Verband Deutscher Biologen e.V.

(Bild: DOI: 10.1021/jacs.5c08354 / Hips / CC BY 4.0) Wissenschaftler am Hips entwickelten eine Plattform zur Produktion von Furanoliden, die effektiv gegen Bakterien und Krebszellen wirken können und vielversprechende Wirkstoffe darstellen.

21.10.2025

PROCESS

at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in partnership with the Helmholtz Centre for Infection Research (HZI

20.10.2025

Bioengineer.org

their biological activity. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

20.10.2025

Phys.org

... die Abteilung „Experimentelle Immunologie“ am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig, lehrt als Professor an ...

17.10.2025

Deutsches Ärzteblatt

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.